Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cMET CAR T cells
- Development stage
- Phase 1
- Lead developer
- University of Pennsylvania
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
cMET CAR T cells are an autologous, RNA-electroporated chimeric antigen receptor (CAR) T-cell therapy designed to target the cell-surface antigen cMET. The CAR construct features an extracellular single-chain antibody variable fragment (scFv) derived from the 5D5 antibody, an IgG4 hinge, a human CD8α transmembrane domain, and intracellular signaling domains composed of CD3ζ and 4-1BB costimulatory modules. This therapy was investigated in a pilot phase I trial for metastatic melanoma and metastatic triple-negative breast cancer (mTNBC), administered intravenously without lymphodepleting chemotherapy. The RNA electroporation ensures transient CAR expression, intended as a safety feature.
- Other names
- RNA-electroporated cMET CAR T cellsmRNA cMET-directed CAR T cells
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on cMET CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cMET CAR T cells.